Distribution agreement with Macopharma

In August 2017 – after concluding a distribution agreement with the French company Macopharma – Dripmate shipped its first part-delivery, which is now on the French market.

The distribution agreement grants Macopharma exclusivity to distribute Dripmate products in France, Great Britain, Belgium, Holland, Luxembourg and Austria.

CEO Carsten Berger comments:
“Prior to our first delivery, Macopharma representatives visited us and our subcontractors and they were very pleased with the quality of our setup and the product itself. Dripmate targets the application range between the usual IV treatment and the very expensive pump treatment which so far have been the only two options. Macopharma supplies products to more than 3,000 hospitals, several of which have more than 1,000 beds. By comparison, in Denmark there are approx. 60 hospitals”.

The first order, which will be delivered continuously over 1-2 months, has a value of DKK 3.6 million.

Macopharma is a distributor company with more than 2,500 employees and a turnover of more than EUR 186 million in 2016.

Recruitment of Chief Technical Officer

Marie-Louise Rasmussen has been appointed Chief Technical Officer (CTO) at Dripmate A/S.

Marie-Louise is responsible for research and development and, together with the CEO of the company, assumes responsibility for the production and purchasing, including responsibility for product release. She will also be the QA/RA management representative.

Marie-Louise has a background as a Master of Science (MSc) from the Technical University of Denmark (DTU).

CEO Carsten Berger comments:

“I am pleased that we have been able to attract Marie-Louise as our CTO. The appointment was made based on a personal reference highlighting the personal and very strong professional skills that Marie-Louise possesses. From the very first day she has shown her abilities and dedication to the company and our product. I am sure that Marie-Louise will be a big asset for the company. “

Manufacturing agreement

Dripmate A/S has entered into an agreement with Tronex A/S for the control of all components, the assembly of Dripmate’s product and the shipment of the final products directly to Dripmate’s customers.

As part of this collaboration, Dripmate A/S will educate the Tronex employees to handle the Dripmate product, as only authorized employees are allowed to handle Dripmate’s products at each production stage. Dripmate undertakes the teaching and the approval of the individual employees.

Before the final delivery to Dripmate’s customers, Dripmate’s internal and external representative of QA/RA must review and compile the Certificate of Conformance (CofC) for each batch and, upon approval, make release for sale, as Dripmate’s product is defined as a Medical Device, classified as “IIa”.

Registration at the Danish Medicines Agency

Dripmate A/S is registered at the Danish Medicines Agency as a medical device manufacturer under LMST Ref.no 2017053175.

New CEO

Following the expiration of the contract with the former CEO, the Board has employed Carsten Berger, who will become the new CEO of the company.

Previously, Carsten Berger has been affiliated with the company as a board member from 2nd of January 2008 till 18th of June 2012. Therefore, he has a thorough knowledge of the company as well as its market and product.

Chairman of the Board, Arne Kaae, comments:
“As Chairman of the Board of Dripmate A/S I am pleased that Carsten Berger joins as the new CEO of the company, as he has a very high level of expertise and management experience, including setting up teams and sales organizations in large companies. I am confident that Carsten, with his financial, sales and management capabilities, will be able to position Dripmate in the large export markets where Dripmate belongs. The company is looking forward to a long and successful cooperation with Carsten.”

Change in the composition of the Board

At the company’s Annual General Meeting on the 25th of May 2017, the composition of the Board was changed, as Bjarne Winther resigned as a result of Chr. Nielsen’s disposal of its shares in the company. New Board members elected; Karsten Lollike, Bo Eklund and Carsten Berger were elected. Arne Kaae and Henrik Oehlenschlæger were re-elected.

Subsequently the Board elected Arne Kaae as Chairman. Arne Kaae has been Chairman of the board since the foundation of the company in 2007.